Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Germany Approves Third Trial of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"IDT Biologika GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine Developed by German Research Group Fails in Early Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Valneva","pharmaFlowCategory":"D","amount":"$39.9 million","upfrontCash":"$35.5 million","newsHeadline":"Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Vaccine","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by IDT Biologika GmbH

    Menu

    IDT Biologika GmbH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              IDT Biologika GmbH

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration

              Details:

              VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging technology. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.

              Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide

              Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001

              Highest Development Status: Approved Product Type: Vaccine

              Partner/Sponsor/Collaborator: Valneva

              Deal Size: $39.9 million Upfront Cash: $35.5 million

              Deal Type: Termination September 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IDT Biologika GmbH

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              COVID-19 Vaccine Developed by German Research Group Fails in Early Trial

              Details:

              A coronavirus vaccine, MVA-SARS-2-S vaccine, developed by the German Centre for Infection Research (DZIF) and vaccine maker IDT Biologika did not prompt the hoped-for immune reaction in early-stage testing on humans.

              Lead Product(s): MVA-SARS-2-S vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-SARS-2-S vaccine

              Highest Development Status: Phase I Product Type: Vaccine

              Recipient: German Center for Infection Research

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IDT Biologika GmbH

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Germany Approves Third Trial of COVID-19 Vaccine Candidate

              Details:

              The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.

              Lead Product(s): MVA-SARS-2-S vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-SARS-2-S vaccine

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY